Goldman Sachs lowered the firm’s price target on Zimmer Biomet (ZBH) to $97 from $106 and keeps a Neutral rating on the shares after its Q3 results. On an organic basis, Zimmer’s growth of 5.0% fell short of management expectations set last quarter of approaching 6.0%, the analyst tells investors in a research note. The company is making progress on its pipeline and portfolio diversification priorities, however, 2025 is on pace to mark the fourth consecutive year of top-line growth deceleration, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet’s Earnings Call: Growth Amid Challenges
- JPMorgan downgrades Zimmer Biomet after ‘step backwards’ quarter
- Zimmer Biomet downgraded to Neutral from Overweight at JPMorgan
- Zimmer Biomet Holdings: Hold Rating Amid Revenue Miss and Market Share Decline
- Zimmer Biomet Holdings: Mixed Q3 Performance and Narrowed Guidance Justify Hold Rating